LPAQTL
MCID: LPP008
MIFTS: 65

Lipoprotein Quantitative Trait Locus (LPAQTL)

Categories: Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Lipoprotein Quantitative Trait Locus

MalaCards integrated aliases for Lipoprotein Quantitative Trait Locus:

Name: Lipoprotein Quantitative Trait Locus 57 37
Coronary Artery Disease 57 12 36 29 54 6 42 44 15 62 17 70
Coronary Artery Disease, Susceptibility to 57 29 6
Myocardial Ischemia 44 17 70
Coronary Arteriosclerosis 12 70
Coronary Artery Anomaly 12 15
Coronary Heart Disease 12 70
Coronary Disease 12 44
Congenital Anomaly of Coronary Artery 12
Coronary Artery Anomaly, Congenital 12
Coronary Artery Abnormality 12
Lpa Deficiency, Congenital 57
Coronary Syndrome 15
Lpaqtl 57
Chd 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11843 DOID:3393
OMIM® 57 618807
KEGG 36 H01742
UMLS 70 C0010054 C0010068 C0151744 more

Summaries for Lipoprotein Quantitative Trait Locus

MedlinePlus : 42 Coronary artery disease (CAD) is the most common type of heart disease. It is the leading cause of death in the United States in both men and women. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. Over time, CAD can also weaken the heart muscle and contribute to heart failure and arrhythmias. Heart failure means the heart can't pump blood well to the rest of the body. Arrhythmias are changes in the normal beating rhythm of the heart. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Lipoprotein Quantitative Trait Locus, also known as coronary artery disease, is related to heart disease and diabetes mellitus, and has symptoms including tremor, angina pectoris and chest pain. An important gene associated with Lipoprotein Quantitative Trait Locus is LPA (Lipoprotein(A)), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Wnt signaling pathway. The drugs Diphenhydramine and Zolpidem have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and bone.

Disease Ontology : 12 An artery disease that is characterized by plaque building up along the inner walls of the arteries of the heart resulting in a narrowing of the arteries and a reduced blood supply to the cardiac muscles.

OMIM® : 57 Lipoprotein(a) is a macromolecular complex in human plasma which represents a quantitative genetic trait with a heritability of 0.7 or higher. Lipoprotein(a) is composed of an LDL-like particle in which apoB (107730) is covalently bound by a single disulfide bond to apolipoprotein(a). Apo(a) has been demonstrated to be the main determinant of the quantitative Lp(a) trait. Variation in the number of plasminogen (PLG)-like kringle (K) IV type 2 tandem repeats in the apo(a) gene is inversely correlated to Lp(a) plasma levels in all populations studied. Several polymorphisms in the Lp(a) gene have been found to affect the apo(a) concentration level (summary by Ogorelkova et al., 1999). (618807) (Updated 20-May-2021)

KEGG : 36 Coronary artery disease (CAD) is one of the leading causes of death globally. CAD is coupled to a pathogenic process in which lipids and lipoproteins accumulate in the subendothelial intimal layer of the vessel wall. A variety of environmental and genetic risk factors are associated with CAD, including hypercholesterolemia, hypertension, obesity, diabetes, and a family history of early CAD. It has been reported that an autosomal dominant form of CAD is caused by the mutation in transcription factor MEF2A. A missense mutation in LRP6, which encodes a co-receptor in the Wnt signaling pathway, has also been identified.

PubMed Health : 62 About coronary artery disease: Coronary artery disease (CAD, also called coronary heart disease, or CHD) is caused by the narrowing of the large blood vessels that supply the heart with oxygen. These are called coronary arteries. Arteries that have become extremely narrow can cause shortness of breath and chest pain during physical activity. If a coronary artery suddenly becomes completely blocked, it can result in a heart attack. CAD can also lead to other health problems like heart failure or heart rhythm problems. Various treatments can be used to reduce the symptoms and the risk of complications.

Related Diseases for Lipoprotein Quantitative Trait Locus

Diseases related to Lipoprotein Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1360)
# Related Disease Score Top Affiliating Genes
1 heart disease 34.2 MIR208A MIR17 MIR155 MIR145 MIR140 MIR126
2 diabetes mellitus 33.2 SOCS1 MIR17 MIR155 MIR145 MIR140 MIR126
3 myocardial infarction 32.9 MIR208A MIR17 MIR155 MIR126 LPA CDKN2B-AS1
4 type 2 diabetes mellitus 32.9 WFDC21P SOCS1 MIR17 MIR126 LPA GAS5
5 hypertension, essential 32.7 MIR92B MIR208A MIR17 MIR155 MIR145 MIR126
6 body mass index quantitative trait locus 11 32.2 SOCS1 MIR17 MIR155 MIR140 MIR126 LPA
7 cardiovascular system disease 32.2 MIR17 MIR155 MIR145 MIR126 LPA CDKN2B-AS1
8 arteries, anomalies of 32.0 MIR17 MIR155 MIR145 MIR140 MIR126
9 lung cancer 32.0 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
10 gastric cancer 31.9 MIR17 MIR155 MIR145 MIR140 MIR126 HOTTIP
11 hepatocellular carcinoma 31.6 SOCS1 MIR182 MIR17 MIR155 MIR145 MIR140
12 esophageal cancer 31.5 MIR145 MIR140 MIR126 HOTTIP H19 GAS5
13 b-cell lymphoma 31.4 SOCS1 MIR17 MIR155 GAS5 CDKN2B CDKN2A
14 lymphoma, non-hodgkin, familial 31.4 SOCS1 MIR182 MIR17 MIR155 MIR140 MIR126
15 lung cancer susceptibility 3 31.4 MIR182 MIR17 MIR145 MIR126 H19 GAS5
16 ovarian disease 31.4 MIR182 MIR17 MIR145 MIR140 MIR126
17 kidney cancer 31.4 MIR182 MIR17 MIR126 H19 GAS5 CDKN2A
18 osteogenic sarcoma 31.3 MIR140 HOTTIP H19 GAS5 CDKN2B-AS1 CDKN2A
19 aortic disease 31.3 MIR17 MIR145 MIR126
20 prostate disease 31.3 MIR182 MIR17 MIR145 MIR140 MIR126 IGF2-AS
21 bladder cancer 31.3 MIR182 MIR17 MIR145 MIR126 H19 GAS5
22 ovarian cancer 31.3 MIR182 MIR17 MIR155 MIR145 MIR140 H19
23 esophageal disease 31.3 MIR182 MIR17 MIR145 MIR140 MIR126
24 melanoma 31.3 WFDC21P MIR182 MIR17 MIR140 H19 GAS5
25 cervical cancer 31.3 MIR17 MIR155 MIR145 MIR126 H19 GAS5
26 aortic valve disease 2 31.3 MIR17 MIR126 LPA
27 aortic aneurysm, familial abdominal, 1 31.2 MIR126 H19 CDKN2B-AS1
28 renal cell carcinoma, nonpapillary 31.2 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
29 leukemia, acute myeloid 31.2 MIR182 MIR17 MIR155 MIR140 MIR126 CDKN2B-AS1
30 intracranial aneurysm 31.2 MIR145 CDKN2B-AS1 CDKN2B CDKN2A
31 connective tissue disease 31.2 MIR17 MIR155 MIR145 MIR140 MIR126
32 overnutrition 31.2 MIR17 MIR155 MIR140 MIR126
33 colonic disease 31.1 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
34 stomach disease 31.1 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
35 large intestine cancer 31.1 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
36 thoracic cancer 31.1 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
37 gastrointestinal system disease 31.1 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
38 myeloma, multiple 31.1 MIR17 MIR145 MIR140 MIR126 H19 GAS5
39 diffuse large b-cell lymphoma 31.0 MIR17 MIR155 MIR145 MIR126 CDKN2A
40 nasopharyngeal carcinoma 31.0 MIR17 MIR140 H19 GAS5 CDKN2B-AS1 CDKN2A
41 rectum cancer 31.0 MIR17 MIR145 MIR126
42 leukemia, acute lymphoblastic 31.0 MIR17 MIR155 MIR126 CDKN2B-AS1 CDKN2B CDKN2A
43 leukemia, chronic myeloid 31.0 SOCS1 MIR17 MIR126 H19 CDKN2B
44 oral squamous cell carcinoma 31.0 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
45 myeloproliferative neoplasm 31.0 SOCS1 MIR17 MIR155 MIR126 H19
46 endometriosis 30.9 MIR145 MIR126 H19 CDKN2B-AS1
47 thyroid carcinoma 30.8 H19 GAS5 CDKN2B-AS1
48 malignant pleural mesothelioma 30.8 MIR17 GAS5 CDKN2A
49 gallbladder disease 30.7 MIR17 MIR145 MIR126
50 bronchial disease 30.7 MIR17 MIR155 MIR140 MIR126

Graphical network of the top 20 diseases related to Lipoprotein Quantitative Trait Locus:



Diseases related to Lipoprotein  Quantitative Trait Locus

Symptoms & Phenotypes for Lipoprotein Quantitative Trait Locus

Clinical features from OMIM®:

618807 (Updated 20-May-2021)

UMLS symptoms related to Lipoprotein Quantitative Trait Locus:


tremor; angina pectoris; chest pain; edema; equilibration disorder; other and unspecified angina pectoris; substernal pain

Drugs & Therapeutics for Lipoprotein Quantitative Trait Locus

PubMed Health treatment related to Lipoprotein Quantitative Trait Locus: 62

The main goals of treatment for CAD are to relieve symptoms and prevent complications. Medication can reduce the symptoms and restrictions in everyday life caused by stable angina . Beta blockers , calcium channel blockers and nitrates are used for this purpose. If that doesn't help, doctors often try to widen the narrowed coronary artery with a procedure using a cardiac catheter . If the arteries are severely narrowed, or if several blood vessels are affected, bypass surgery may be considered. This involves taking a blood vessel from elsewhere in the body and using it to redirect blood around the blocked coronary artery (bypassing it). There are things you can do on your own to help prevent complications like a heart attack or heart failure : eating a healthy diet and getting enough exercise are two examples. If you smoke, you could try to give it up. Also, there are a number of different medications that can prevent complications and increase life expectancy. These include the following: Low doses of acetylsalicylic acid (the drug in medicines like "Aspirin ") to prevent blood clots Statins to protect the blood vessels Beta blockers to reduce the strain on the heart (especially in people with heart failure or high blood pressure )

Drugs for Lipoprotein Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 748)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Zolpidem Approved Phase 4 82626-48-0 5732
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Colchicine Approved Phase 4 64-86-8 6167 2833
5
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
6
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
7
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Ephedrine Approved Phase 4 299-42-3 9294
10
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
11
Pseudoephedrine Approved Phase 4 90-82-4 7028
12
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
13
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
14
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
15
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
18
Nitric Oxide Approved Phase 4 10102-43-9 145068
19
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
20
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
21
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
22
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
23
Enoxaparin Approved Phase 4 9005-49-6 772
24
Insulin glargine Approved Phase 4 160337-95-1
25
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
26
Milrinone Approved Phase 4 78415-72-2 4197
27
Dobutamine Approved Phase 4 34368-04-2 36811
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
Ranitidine Approved, Withdrawn Phase 4 66357-59-3, 66357-35-5, 82530-72-1 3001055
30
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
31
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
32
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
33
Insulin aspart Approved Phase 4 116094-23-6 16132418
34
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
35
Acetaminophen Approved Phase 4 103-90-2 1983
36
Etomidate Approved Phase 4 33125-97-2 36339 667484
37
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
38
Probucol Approved, Investigational Phase 4 23288-49-5 4912
39
Glimepiride Approved Phase 4 93479-97-1 3476
40
Famotidine Approved Phase 4 76824-35-6 3325
41
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
42
Iodine Approved, Investigational Phase 4 7553-56-2 807
43
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
44
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
45
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
46
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
47
Linagliptin Approved Phase 4 668270-12-0 10096344
48
Glyburide Approved Phase 4 10238-21-8 3488
49
Trandolapril Approved Phase 4 87679-37-6 5484727
50
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639

Interventional clinical trials:

(show top 50) (show all 5919)
# Name Status NCT ID Phase Drugs
1 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
2 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
3 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
4 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
5 Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study - Unknown status NCT01453712 Phase 4
6 Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study Unknown status NCT00513149 Phase 4 Clopidogrel
7 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
8 Evaluation of the Strategy of "One-stop" Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease Unknown status NCT03563768 Phase 4
9 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
10 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
11 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
12 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
13 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
14 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
15 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
16 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
17 Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus. Unknown status NCT01735825 Phase 4
18 Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study Unknown status NCT03679091 Phase 4 low-dose ticagrelor;Clopidogrel
19 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
20 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
21 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
22 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
23 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
24 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
25 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
26 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
27 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
28 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
29 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
30 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
31 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
32 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
33 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
34 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
35 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
36 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
37 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
38 Cardiac Metabolic Modulator Treatment for Improvement of Left Ventricular Diastolic Function in Patients With Coronary Heart Disease: a Prospective, Randomized Controlled Study Unknown status NCT03887013 Phase 4 Trimetazidine
39 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
40 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
41 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
42 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
43 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
44 Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
45 Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study Unknown status NCT03700645 Phase 4 Allopurinol
46 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
47 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
48 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
49 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
50 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin

Search NIH Clinical Center for Lipoprotein Quantitative Trait Locus

Inferred drug relations via UMLS 70 / NDF-RT 51 :


atorvastatin
Atorvastatin calcium
cerivastatin
Cerivastatin sodium
Cholestyramine Resin
Clofibrate
colesevelam
Colesevelam hydrochloride
Colestipol
Colestipol Hydrochloride
Dextrothyroxine
Dextrothyroxine Sodium
eptifibatide
Fenofibrate
Fish Liver Oils
fluvastatin
Fluvastatin sodium
Gemfibrozil
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Lovastatin
Pravastatin
Pravastatin Sodium
Probucol
rosuvastatin
Simvastatin
Sulfinpyrazone
tirofiban
TIROFIBAN HYDROCHLORIDE

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lipoprotein Quantitative Trait Locus cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lipoprotein Quantitative Trait Locus:
CD34+ stem cells for treatment of congestive heart failure
Embryonic/Adult Cultured Cells Related to Lipoprotein Quantitative Trait Locus:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120

Cochrane evidence based reviews: coronary artery disease

Genetic Tests for Lipoprotein Quantitative Trait Locus

Genetic tests related to Lipoprotein Quantitative Trait Locus:

# Genetic test Affiliating Genes
1 Coronary Artery Disease 29
2 Coronary Artery Disease, Susceptibility to 29

Anatomical Context for Lipoprotein Quantitative Trait Locus

MalaCards organs/tissues related to Lipoprotein Quantitative Trait Locus:

40
Heart, Endothelial, Bone, Kidney, Bone Marrow, Liver, Neutrophil

Publications for Lipoprotein Quantitative Trait Locus

Articles related to Lipoprotein Quantitative Trait Locus:

(show top 50) (show all 31607)
# Title Authors PMID Year
1
A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. 61 54 6
10591678 1999
2
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. 54 61 6
8675673 1995
3
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. 57 61
17569884 2007
4
The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. 54 6
12843189 2003
5
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. 61 6
8770857 1996
6
Relationship between long non-coding RNA polymorphism and the risk of coronary artery disease: A protocol for systematic review and meta-analysis. 42 61
33761682 2021
7
Integration of summary data from GWAS and eQTL studies identified novel risk genes for coronary artery disease. 42 61
33725943 2021
8
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. 57
31865966 2019
9
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. 6
31358993 2019
10
HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. 6
28126521 2017
11
A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. 57
28444229 2017
12
Genetic associations with valvular calcification and aortic stenosis. 57
23388002 2013
13
Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. 47 61
21195052 2011
14
Paraoxonase-1 is a major determinant of clopidogrel efficacy. 6
21170047 2011
15
Circulating microRNAs in patients with coronary artery disease. 61 47
20595655 2010
16
Lipoprotein(a) and risk of type 2 diabetes. 57
20511445 2010
17
Gene expression profiling in whole blood of patients with coronary artery disease. 47 61
20528768 2010
18
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. 57
20032323 2009
19
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. 47 61
19371267 2009
20
Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. 57
18560444 2008
21
Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. 57
16840570 2006
22
A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). 57
15523644 2004
23
Paraoxonase 1 polymorphisms and survival. 6
15241482 2004
24
Assessing the function of genetic variants in candidate gene association studies. 6
15266341 2004
25
Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. 6
15240653 2004
26
G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. 6
14707024 2004
27
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. 6
14671192 2003
28
Lp(a) lipoprotein, vascular disease, and mortality in the elderly. 57
14645638 2003
29
Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. 6
12082503 2002
30
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 6
11918623 2002
31
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. 6
11888590 2002
32
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 6
11889198 2002
33
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. 6
11810302 2002
34
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 6
11788650 2002
35
Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. 57
11698280 2001
36
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 6
11335891 2001
37
Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. 57
11285247 2001
38
The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. 6
11238489 2001
39
The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. 6
10843189 2000
40
Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians. 57
10484779 1999
41
The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. 6
10430617 1999
42
Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. 6
10084586 1999
43
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 6
9661650 1998
44
Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. 57
9577282 1998
45
Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? 6
9443884 1998
46
The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. 6
9385372 1997
47
Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. 6
9215303 1997
48
Lipoprotein (a): its role in childhood thromboembolism. 57
9164807 1997
49
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 6
9011577 1997
50
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. 6
8647950 1996